Last reviewed · How we verify
Insulin Faster Aspart
Insulin Faster Aspart is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels.
Insulin Faster Aspart is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels. Used for Management of hyperglycemia in adults and children with type 1 diabetes and type 2 diabetes, Adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes.
At a glance
| Generic name | Insulin Faster Aspart |
|---|---|
| Also known as | Fiasp |
| Sponsor | Jesús Moreno Fernández |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating glucose uptake in cells, inhibiting glucose production in the liver, and slowing gastric emptying to reduce postprandial glucose spikes. This results in a rapid decrease in blood glucose levels, making it suitable for managing hyperglycemia in patients with diabetes.
Approved indications
- Management of hyperglycemia in adults and children with type 1 diabetes and type 2 diabetes
- Adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes
Common side effects
- Hypoglycemia
- Nausea
- Injection site reactions
Key clinical trials
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (PHASE3)
- Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (PHASE4)
- An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
- A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump (PHASE1)
- Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (PHASE4)
- Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Faster Aspart CI brief — competitive landscape report
- Insulin Faster Aspart updates RSS · CI watch RSS
- Jesús Moreno Fernández portfolio CI